Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc.
Your view on SHPH
Overview
What the company does, where it operates, and who runs it.
About Shuttle Pharmaceuticals Holdings, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Christopher Robert Cooper BBA, MBA
- Headquarters
- One Research Court, Gaithersburg, MD, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Christopher Robert Cooper BBA, MBA
- Headquarters
- One Research Court, Gaithersburg, MD, US
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy.
Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Shuttle Pharmaceuticals Holdings, Inc., and the rating behind it. SHPH last traded at $3.53; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Shuttle Pharmaceuticals Holdings, Inc.. Starting points for Shuttle Pharmaceuticals Holdings, Inc.: EPS -$21.51, beta 1.22 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Shuttle Pharmaceuticals Holdings, Inc.. Shuttle Pharmaceuticals Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Shuttle Pharmaceuticals Holdings, Inc.. Trailing twelve-month EPS for Shuttle Pharmaceuticals Holdings, Inc. stands at -$21.51. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Shuttle Pharmaceuticals Holdings, Inc.. Shuttle Pharmaceuticals Holdings, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Shuttle Pharmaceuticals Holdings, Inc. valued side by side against its closest peers. Shuttle Pharmaceuticals Holdings, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Shuttle Pharmaceuticals Holdings, Inc., and how their positions are changing. At a $2.1M market value, institutional positions materially move Shuttle Pharmaceuticals Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Shuttle Pharmaceuticals Holdings, Inc. executives and directors. Shares of Shuttle Pharmaceuticals Holdings, Inc. have traded between $1.85 and $25.25 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Shuttle Pharmaceuticals Holdings, Inc.. Shuttle Pharmaceuticals Holdings, Inc. is a $2.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Shuttle Pharmaceuticals Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Shuttle Pharmaceuticals Holdings, Inc.. Coverage tracks Shuttle Pharmaceuticals Holdings, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.